The BSH Guidelines Official Podcast-logo

The BSH Guidelines Official Podcast

Medical

Written by expert consultants and clinical scientists currently practising in the UK, the BSH Guidelines provide up-to-date evidence-based guidance on the diagnosis and treatment of haematological diseases. Self accreditation Listen to two podcasts and earn one CPD point via self-accreditation Join our Guidelines Newsletter to be notified when new guidelines/good practice papers are published by going into your members account under MyBSH. Non members can email bshguidelines@b-s-h.org.uk to sign up for updates.

Location:

United States

Description:

Written by expert consultants and clinical scientists currently practising in the UK, the BSH Guidelines provide up-to-date evidence-based guidance on the diagnosis and treatment of haematological diseases. Self accreditation Listen to two podcasts and earn one CPD point via self-accreditation Join our Guidelines Newsletter to be notified when new guidelines/good practice papers are published by going into your members account under MyBSH. Non members can email bshguidelines@b-s-h.org.uk to sign up for updates.

Language:

English


Episodes
Ask host to enable sharing for playback control

Diagnosis and management of heparin-induced thrombocytopenia: Third edition

4/19/2024
A podcast recording by Dr Deepa J. Arachchillage on the guideline: Diagnosis and management of heparin-induced thrombocytopenia: Third edition.

Duration:00:26:29

Ask host to enable sharing for playback control

Diagnosis and management of marginal zone lymphomas

4/8/2024
The objective of this podcast presented by Kim Linton and Renata Walewska is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with marginal zone lymphoma (MZL).

Duration:00:30:00

Ask host to enable sharing for playback control

Guideline on the Investigation and management of a raised serum ferritin

4/4/2024
Guideline on the Investigation and management of a raised serum ferritin: A podcast recording of a conversation between Dr Jenny Tam and Dr Wayne Thomas.

Duration:00:16:34

Ask host to enable sharing for playback control

Significant Haemoglobinopathies: a guideline for screening and diagnosis

11/29/2023
Antenatal screening/testing of pregnant women should be carried out according to the guidelines of the National Health Service (NHS) Sickle Cell and Thalassaemia Screening Programme. Newborn screening and, when necessary, follow-up testing and referral, should be carried out according to the guidelines of the NHS Sickle Cell and Thalassaemia Screening Programme. All babies under 1 year of age arriving in the United Kingdom should be offered screening for sickle cell disease (SCD). Preoperative screening for SCD should be carried out in patients from ethnic groups in which there is a significant prevalence of the condition. Emergency screening with a sickle solubility test must always be followed by definitive analysis. Laboratories performing antenatal screening should utilise methods that are capable of detecting significant variants and are capable of quantitating haemoglobins A2 and F at the cut-off points required by the national antenatal screening programme. The laboratory must ensure a provisional report is available for antenatal patients within three working days from sample receipt.

Duration:00:28:30

Ask host to enable sharing for playback control

Diagnosis and management of Mantle Cell Lymphoma

11/21/2023
The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with mantle cell lymphoma.

Duration:00:11:30

Ask host to enable sharing for playback control

Investigation and management of the monoclonal gammopathy of undetermined significance (MGUS)

8/2/2023
This Good Practice Paper podcast provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.

Duration:00:19:46

Ask host to enable sharing for playback control

Guideline on the investigation and management of acute transfusion reactions

7/12/2023

Duration:00:19:06

Ask host to enable sharing for playback control

Haematological management of major haemorrhage

6/7/2023
Haematological management of major haemorrhage: A podcast recording of a conversation between Prof Simon Stanworth and Dr Heidi Doughty.

Duration:00:21:07

Ask host to enable sharing for playback control

Anticoagulant management of pregnant individuals with mechanical heart valves

5/26/2023
A BSH Guideline on the Anticoagulant management of pregnant individuals with mechanical heart valves presented by Dr Will Lester.

Duration:00:16:57

Ask host to enable sharing for playback control

EHA 2022: The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper

12/21/2022
Guideline session at EHA Conference 2022 on The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper

Duration:00:45:21

Ask host to enable sharing for playback control

Management of secondary central nervous system lymphoma: A British Society for Haematology Good Practice Paper

12/8/2022
Secondary central nervous system (CNS) lymphoma (SCNSL) refers to lymphoma that has spread to the CNS concurrently with, or following treatment for, systemic lymphoma. There are three clinically distinct scenarios: CNS lymphoma (CNSL) is associated with inferior outcomes, which may be attributed to several factors: poor CNS penetrance of chemotherapeutics, including RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone),1 impaired neurocognitive function and patient performance status (PS) contributing to increased treatment toxicity,2, 3 and recurrent genetic aberrations conferring treatment resistance.4-6 The rarity and heterogeneity of SCNSL also limits the evidence base for treatment recommendations, with poor outcomes potentially attributable at least in part to lack of optimised treatment protocols. This good practice paper focuses on diffuse large B-cell lymphoma (DLBCL), the most common SCNSL subtype. It covers diagnostic and therapeutic aspects of care for the three SCNSL scenarios and multiply relapsed SCNSL. Treatment recommendations are framed by patient fitness and treatment intent.

Duration:00:17:06

Ask host to enable sharing for playback control

Guidelines for thrombophilia testing

11/28/2022
This guideline updates and widens the scope of the previous British Society for Haematology (BSH) Clinical guidelines for testing for heritable thrombophilia1 to include both heritable and acquired thrombophilia. The term thrombophilia is generally used to describe hereditary and/or acquired conditions associated with an increased predisposition to thrombosis. Heritable thrombophilia refers to genetic disorders of specific haemostatic proteins. These guidelines focus only on the factors that are identified from laboratory testing and therefore exclude disorders such as cancer, inflammatory conditions and obesity that are associated with thrombosis through multiple mechanisms.

Duration:00:24:40

Ask host to enable sharing for playback control

Good Practice Paper for management of older patients with frailty and acute myeloid leukaemia

8/26/2022
Audio commentary from Dr Mike Dennis on the good practice paper - management of older patients with frailty and acute myeloid leukaemia.

Duration:00:14:47

Ask host to enable sharing for playback control

Guideline for the first-line management of Classical Hodgkin Lymphoma

7/19/2022
Audio commentary by Dr George Follows.

Duration:00:29:40

Ask host to enable sharing for playback control

BSH ASM: Guidelines Session: GPP Cytomegalovirus serological testing in potential allogeneic haematopoietic stem cell transplant recipients

6/30/2022
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022 Dr Suzy Morton on the Good Practice Paper Cytomegalovirus serological testing in potential allogeneic haematopoietic stem cell transplant recipients. Dr Suzy Morton is a Consultant in clinical haematology and blood transfusion at the Queen Elizabeth Hospital, University Hospitals Birmingham and NHS Blood and Transplant. She is the transfusion representative on the West Midlands Haematology Specialty Training Committee and the educational lead for haematology SpRs at QEHB. Suzy is a transfusion representative on the BSH Education committee.
Ask host to enable sharing for playback control

BSH ASM: Guidelines Session Presentation: Preoperative patient blood management during the SARS-CoV-2 pandemic

6/27/2022
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022 Dr Katie Hands presents on the Good Practice Paper Preoperative patient blood management during the SARS-CoV-2 pandemic. Katie Hands is a Consultant Haematologist with the Scottish National Blood Transfusion Service (SNBTS) based at Ninewells Hospital, Dundee. She is a member of the British Society for Haematology Transfusion Task Force and is involved in the preparation of evidence-based guidelines relating to all aspects of blood transfusion in the United Kingdom.
Ask host to enable sharing for playback control

BSH ASM: Guidelines Session Presentation: Myelodysplastic syndromes

6/23/2022
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022 Dr Austin Kulasekararaj presents on the Myelodysplastic syndromes covering the BSH Guidelines on the diagnosis and prognosis of adult myelodysplastic syndromes and Guidelines on the management of adult myelodysplastic syndromes. Dr Austin Kulasekararaj is a Consultant Haematologist at the King's College Hospital London. His special interests are adult myelodysplastic syndromes, acute leukaemia and aplastic anaemia.
Ask host to enable sharing for playback control

BSH ASM: Guidelines Session Presentation Diagnosis and Management of Waldenstrom Macroglobulinaemia

6/20/2022
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022 Dr Dima ElSharkawi presents the Guideline on the Diagnosis and Management of Waldenstrom Macroglobulinaemia. Dr Dima El-Sharkawi is a Consultant Haematologist and part of the haematological malignancy diagnostic services at the Royal Marsden NHS Foundation Trust. She is also a Trustee for the UK Charity for Waldenström macroglobulinaemia (WMUK). Dr El-Sharkawi's special interests are in CLL, rare leukaemias and lymphomas including Waldenström macroglobulinaemia.
Ask host to enable sharing for playback control

Guideline for the treatment of chronic lymphocytic leukaemia

6/13/2022
Dr Nilima Parry Jones and Dr Renata Walewska present a podcast on the Guideline for the treatment of chronic lymphocytic leukaemia Both Dr Parry Jones and Dr Walewska discuss the guideline in three main parts: 1) Choice of treatment for CLL in front line and relapsed settings 2) Impact to immune dysregulation in respect of anti-microbial prophylaxis and vaccination 3) Challenges of the Covid pandemic, the evolving evidence on vaccine response, treatment of patients with Covid and antiviral and monoclonal antibodies Dr Nilima Parry-Jones is a Consultant Haematologist at the Aneurin Bevan Local Health, Wales and an executive member of the UK CLL Forum. She is the Chair of the BSH Haematology Oncology Task Force. Dr Renata Walewska is a Consultant Haematologist at the Royal Bournemouth Hospital and Chair of the UK CLL Forum.

Duration:00:30:09

Ask host to enable sharing for playback control

The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper

6/7/2022
Dr Noemi Roy and Dr Roberta Russo present a podcast on the The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper Dr Roy and Dr Russo discuss the good practice paper in three main parts: 1) Focus on rare anaemias: ( Diamond-Blackfan Anaemia, Congenial dyserythropoietic anaemia (CDA), Sideroblastic anaemia and Red cell membrane/cation leaking and enzyme disorders 2) Next generation sequencing (NGS) 3) How and why we need to interpret genetic variants carefully The use of next-generation sequencing (NGS) in the diagnosis of rare inherited anaemias is increasingly common, as evidenced by a growing number of publications describing its clinical utility.1-6 Excluding disorders of globin synthesis, rare anaemias include Diamond–Blackfan anaemia (DBA), congenital dyserythropoietic anaemias (CDA), congenital sideroblastic anaemias (CSA) and disorders of red cell membrane and enzymes. Other forms of genetic anaemias can also be considered while establishing NGS panels, in particular genetic syndromes where anaemia comprises one of the constellation of symptoms. Dr Noemi Roy is a Consultant Haematologist at Oxford University Hospitals NSH Foundation Trust and honorary senior clinical lecturer in haematology at the University of Oxford. She is a BSH General Haematology Task Force member and Chair for the Guidelines Executive committee for the European Hematology Association. She is the rare anaemia representative at the National Haemoglobinopathy Panel. Her main interests are haemoglobinopathies and rare inherited anaemias, and in particular the genetic investigation of inherited anaemias, including whole genome sequencing. Dr Roberta Russo is an assistant professor in medical genetics at the University of Naples "Federico II". She has dealt with the study of the genetics of rare disorders, particularly hereditary anaemias, since 2008. Her main interest was the study of Congenital Dyserythropoietic Anaemias (CDAs), mainly CDA type II, genetics and genomics of red cell anaemias and blood cell defects . She contributed first hand to the identification of the causative genes of rare anaemias. Subsequently, she became one of the leading scientists for the genetics and epidemiology of CDAs. Since 2015, she has been dealing with the application of next generation sequencing to the clinical and medical definition of patients affected by this conditions. In 2011, she won the Young Investigator Award by the American Journal of Hematology for her study on the epidemiology of this disorder.

Duration:00:25:01